A protein therapeutic modality founded on molecular regulation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 39, 2011, Pages 16206-16211

  Wright, Chapman M ^a   Wright, R Clay ^a   Eshleman, James R ^b   Ostermeier, Marc ^a  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Directed evolution; Enzyme prodrug therapy; Protein engineering; Protein switch

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ALLOSTERISM; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ACTIVITY; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXIA; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

BREAST NEOPLASMS; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; RECOMBINANT PROTEINS;

EID: 80053651953     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1102803108     Document Type: Article

References (38)

1. Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discov 7:21-39.
2. Verdine GL, Walensky LD (2007) The challenge of drugging undruggable targets in cancer: Lessons learned from targeting BCL-2 family members. Clin Cancer Res 13:7264-7270.
3. Guntas G, Ostermeier M (2004) Creation of an allosteric enzyme by domain insertion. J Mol Biol 336:263-273. (Pubitemid 38102347)
4. Guntas G, Mitchell SF, Ostermeier M (2004) A molecular switch created by in vitro recombination of nonhomologous genes. Chem Biol 11:1483-1487. (Pubitemid 39527274)
5. Guntas G, Mansell TJ, Kim JR, Ostermeier M (2005) Directed evolution of protein switches and their application to the creation of ligand-binding proteins. Proc Natl Acad Sci USA 102:11224-11229. (Pubitemid 41153802)
6. Wright CM, Majumdar A, Tolman JR, Ostermeier M (2010) NMR characterization of an engineered domain fusion between maltose binding protein and TEM1 beta-lactamase provides insight into its structure and allosteric mechanism. Proteins 78:1423-1430.
7. Sohka T, et al. (2009) An externally tunable bacterial band-pass filter. Proc Natl Acad Sci USA 106:10135-10140.
8. Zhong H, et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830-5835.
9. Mabjeesh NJ, Amir S (2007) Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 22:559-572. (Pubitemid 46647268)
10. Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625-634.
11. Huang LE, Gu J, Schau M, Bunn HF (1998) Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95:7987-7992.
12. Yu AY, et al. (1998) Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol 275:L818-826.
13. Semenza GL (2004) Hydroxylation of HIF-1: Oxygen sensing at the molecular level. Physiology (Bethesda) 19:176-182.
14. Sun HC, et al. (2007) Expression of hypoxia-inducible factor-1a and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol 30:1359-1367.
15. Dales JP, et al. (2005) Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: Retrospective study in a series of 745 patients. Int J Cancer 116:734-739.
16. Akakura N, et al. (2001) Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61:6548-6554. (Pubitemid 32783263)
17. Khandrika L, et al. (2009) Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene 28:1248-1260.
18. Liao D, Corle C, Seagroves TN, Johnson RS (2007) Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67:563-572. (Pubitemid 46192193)
19. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM (2000) Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6:1335-1340. (Pubitemid 32001016)
20. Freedman SJ, et al. (2002) Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci USA 99:5367-5372. (Pubitemid 34411554)
21. Freedman SJ, et al. (2003) Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2. Nat Struct Biol 10:504-512. (Pubitemid 36792900)
22. Korkegian A, Black ME, Baker D, Stoddard BL (2005) Computational thermostabilization of an enzyme. Science 308:857-860. (Pubitemid 40629266)
23. Kievit E, et al. (1999) Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 59:1417-1421. (Pubitemid 29160102)
24. Crystal RG, et al. (1997) Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 8:985-1001. (Pubitemid 27270161)
25. Mahan SD, Ireton GC, Stoddard BL, Black ME (2004) Alanine-scanning mutagenesis reveals a cytosine deaminase mutant with altered substrate preference. Biochemistry 43:8957-8964. (Pubitemid 38924430)
26. Mahan SD, Ireton GC, Knoeber C, Stoddard BL, Black ME (2004) Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy. Protein Eng Des Sel 17:625-633. (Pubitemid 39665399)
27. Dial R, Sun ZY, Freedman SJ (2003) Three conformational states of the p300 CH1 domain define its functional properties. Biochemistry 42:9937-9945. (Pubitemid 37012869)
28. Dang DT, et al. (2006) Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 66:1684-1936.
29. Thant AA, et al. (2008) Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells. Anticancer Res 28:3579-3592.
30. Shibata T, Giaccia AJ, Brown JM (2000) Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 7:493-498. (Pubitemid 30156563)
31. Epstein AC, et al. (2001) Celegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54. (Pubitemid 32972036)
32. Zhao D, Ran S, Constantinescu A, Hahn EW, Mason RP (2003) Tumor oxygen dynamics: Correlation of in vivo MRI with histological findings. Neoplasia 5:308-318. (Pubitemid 37048608)
33. Greco O, Dachs GU (2001) Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives. J Cell Physiol 187:22-36. (Pubitemid 32195242)
34. Russell PJ, Khatri A (2006) Novel gene-directed enzyme prodrug therapies against prostate cancer. Expert Opin Investig Drugs 15:947-961. (Pubitemid 44177846)
35. Schepelmann S, Springer CJ (2006) Viral vectors for gene-directed enzyme prodrug therapy. Curr Gene Ther 6:647-670. (Pubitemid 44890548)
36. Marignol L, et al. (2009) Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: A highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro. J Gene Med 11:169-179.
37. Yan M, et al. (2010) A novel intracellular protein delivery platform based on single-protein nanocapsules. Nat Nanotechnol 5:48-53.
38. Cronican JJ, et al. (2010) Potent delivery of functional proteins into Mammalian cells in vitro and in vivo using a supercharged protein. ACS Chem Biol 5:747-752.